Immuno Oncology Assays Market Report Covers Key Segments, Regional Developments, and Leading Competitors

The Business Research Company

Immuno Oncology Assays Market

The Business Research Company’s Immuno Oncology Assays Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, October 20, 2026 /EINPresswire.com/ -- Understanding the rapid expansion of the immuno oncology assays market is crucial as cancer research and personalized treatment approaches evolve. This sector is experiencing significant growth driven by advances in immunotherapy and biomarker technologies, creating promising opportunities for both researchers and healthcare providers worldwide.

Immuno Oncology Assays Market Size and Growth Outlook
The immuno oncology assays market has witnessed substantial expansion, with its valuation expected to rise from $4.88 billion in 2025 to $5.52 billion in 2026. This growth corresponds to a compound annual growth rate (CAGR) of 13.1%, reflecting strong momentum in recent years. Looking ahead, the market is projected to continue growing rapidly, reaching $8.9 billion by 2030 at a CAGR of 12.7%. Key factors behind this surge include the increasing global incidence of cancer, heightened investment in cancer immunotherapy research, broader acceptance of biomarker-driven cancer diagnostics, and the expanding role of personalized medicine. Additionally, a surge in clinical oncology research has further accelerated this market’s development.

Download a free sample of the immuno oncology assays market report:
https://www.thebusinessresearchcompany.com/sample_request?id=86621071&type=smp&name=Immuno%20Oncology%20Assays%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Factors Supporting Market Growth in Immuno Oncology Assays
One major contributor to the market’s rise is the growing demand for advanced immune profiling assays. These tools help provide comprehensive insights into a patient’s immune response, enabling better treatment strategies. Parallel to this, precision oncology approaches are becoming more widely adopted, as they allow therapies to be tailored to individual patients’ tumor characteristics.

Another driver is the development of novel immunotherapies for cancer treatment. Alongside this, the use of predictive biomarkers to guide treatment decisions is becoming increasingly prevalent. Collaborations between pharmaceutical companies and research institutions are also expanding, accelerating innovation and adoption of new assays.

View the full immuno oncology assays market report:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-assays-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Key Trends Shaping the Future of Immuno Oncology Assays
Multiplex immuno oncology assays, which enable simultaneous analysis of multiple biomarkers, are gaining traction. This facilitates a more detailed understanding of tumor microenvironments and immune responses, benefiting both research and clinical practice.

There is also a growing emphasis on companion diagnostics to support cancer immunotherapy development. These diagnostics help identify patients most likely to benefit from specific treatments. Interest in immune profiling as a personalized oncology strategy continues to rise, as does the use of biomarker-based approaches in clinical trials. Furthermore, demand is increasing for advanced assay platforms that can accelerate cancer research workflows and improve efficiency.

Understanding Immuno Oncology Assays and Their Role
Immuno-oncology assays are specialized laboratory tests designed to evaluate the immune system’s activity against cancer. They measure various factors such as biomarkers, immune cell functions, cytokine levels, and gene expression related to tumors. These assays are essential tools for researchers and clinicians to assess the effectiveness of cancer immunotherapies, monitor treatment outcomes, and identify predictive biomarkers that can inform personalized treatment plans.

How Increasing Cancer Prevalence Drives Market Expansion
The rising number of cancer cases worldwide is a critical force propelling the immuno-oncology assays market forward. Cancer prevalence refers to the count of individuals diagnosed with any cancer type within a certain population or time frame, serving as an indicator of disease burden and healthcare demand. Risk factors such as tobacco and alcohol use contribute significantly to the increasing cancer incidence by exposing individuals to carcinogens that damage cells and elevate mutation rates. This includes cancers of the lung, liver, oral cavity, and esophagus. Immuno-oncology assays play a pivotal role in cancer care by detecting tumor-specific biomarkers, assessing immune responses, aiding in personalized immunotherapy choices, and tracking treatment success. For example, data from the Centers for Disease Control and Prevention in January 2026 highlighted that the United States had approximately 1.85 million new cancer diagnoses in 2022, with cancer causing 613,349 deaths in 2023. Such statistics highlight why the growing cancer burden is boosting the demand for immuno-oncology assays.

Regional Leadership in the Immuno Oncology Assays Market
In 2025, North America held the largest share of the immuno oncology assays market, benefiting from advanced healthcare infrastructure and extensive research activities. However, the Asia-Pacific region is expected to be the fastest-growing market during the forecast period, driven by increasing healthcare investments and rising cancer incidence in these countries. The market report covers multiple regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa, providing a broad perspective on global developments in this sector.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X